Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 5, 2014, Pages 392-399

  Orizondo, Ryan A ^a   Babcock, Charlene Irvin ^b   Fabiilli, Mario L ^b   Pavlovsky, Leonid ^a   Fowlkes, J Brian ^b   Younger, John G ^b   Cook, Keith E ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

liquid ventilation; pulmonary antibiotic delivery; respiratory infection

Indexed keywords

FLUOROCARBON; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIOFILM; CONTROLLED STUDY; DENSITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG STABILITY; EMULSION; FLOW KINETICS; NONHUMAN; PSEUDOMONAS AERUGINOSA; RAT; SURFACE TENSION; VISCOSITY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; LUNG; MALE; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS; SPRAGUE DAWLEY RAT; STANDARDS; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FLUOROCARBONS; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE TENSION; TIME FACTORS; TOBRAMYCIN; VISCOSITY;

EID: 84907914063     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1058     Document Type: Article

References (44)

1. Davies JC, and Bilton D: Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54:628-640.
2. Head NE, and Yu H: Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect Immun. 2004;72:133-144.
3. Hoiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PO, Molin S, Givskov M, Tolker-Nielsen T, and Bjarnsholt T: The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3:55-65.
4. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, and Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122: 219-226.
5. Cole PJ: The role of nebulized antibiotics in treating serious respiratory infections. J Chemother. 2001;13:354-362.
6. Marier JF, Brazier JL, Lavigne J, and Ducharme MP: Li-posomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother. 2003;52:247-252.
7. Labiris NR, and Dolovich MB: Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J Clin Pharmacol. 2003;56:588-599.
8. Kuhn RJ: Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy. 2002;22:80S-85S.
9. Rubin BK: Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008;21: 71-76.
10. 99mTc-tobramycin using pulmonary surfactant as vehicle. Br J Pharmacol. 1999;126:1091-1096.
11. Baba A, Kim YK, Zhang H, Liu M, and Slutsky AS: Per-fluorocarbon blocks tumor necrosis factor-a-induced inter-leukin-8 release from alveolar epithelial cells in vitro. Crit Care Med. 2000;28:1113-1118.
12. Burkhardt W, Koehne P, Wissel H, Graf S, Proquitte H, Wauer RR, and Rudiger M: Intratracheal perfluorocarbons diminish LPS-induced increase in systemic TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2008;294:1043-1048.
13. Koch T, Ragaller M, Haufe D, Hofer A, Grosser M, Al-brecht DM, Kotzsch M, and Luther T: Perfluorohexane attenuates proinflammatory and procoagulatory response of activated monocytes and alveolar macrophages. Anesthe-siology. 2001;94:101-109.
14. Thomassen MJ, Buhrow LT, and Wiedemann HP: Per-flubron decreases inflammatory cytokine production by human alveolar macrophages. Crit Care Med. 1997;25: 2045-2047.
15. Varani J, Hirschl RB, Dame M, and Johnson K: Per-fluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy. Shock. 1996;6:339-344.
16. Croce MA, Fabian TC, Patton JH Jr, Melton SM, Moore M, and Trenthem LL: Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients. J Trauma. 1998;45:273-280; discussion 280-282.
17. Hirschl RB, Pranikoff T, Wise C, Overbeck MC, Gauger P, Schreiner RJ, Dechert R, and Bartlett RH: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA. 1996;275:383-389.
18. van Eeden SF, Klut ME, Leal MA, Alexander J, Zonis Z, and Skippen P: Partial liquid ventilation with perfluorocarbon in acute lung injury: light and transmission electron microscopy studies. Am J Respir Cell Mol Biol. 2000;22:441-450.
19. Dickson EW, Doern GV, Trevino L, Mazzoni M, and Heard SO: Prevention of descending pneumonia in rats with perflubron-delivered tobramycin. Acad Emerg Med. 2003;10:1019-1023.
20. Matsuda K, Sawada S, Bartlett RH, and Hirschl RB: Effect of ventilatory variables on gas exchange and hemody-namics during total liquid ventilation in a rat model. Crit Care Med. 2003;31:2034-2040.
21. Pohlmann JR, Brant DO, Daul MA, Reoma JL, Kim AC, Osterholzer KR, Johnson KJ, Bartlett RH, Cook KE, and Hirschl RB: Total liquid ventilation provides superior respiratory support to conventional mechanical ventilation in a large animal model of severe respiratory failure. ASAIO J. 2011;57:1-8.
22. Ricard JD, Iserin F, Dreyfuss D, and Saumon G: Perflubron dosing affects ventilator-induced lung injury in rats with previous lung injury. Crit Care Med. 2007;35:561-567.
23. Hirschl RB, Croce M, Gore D, Wiedemann H, Davis K, Zwischenberger J, and Bartlett RH: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;165:781-787.
24. Kacmarek RM, Wiedemann HP, Lavin PT, Wedel MK, Tutuncu AS, and Slutsky AS: Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;173:882-889.
25. Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, DeLemos R, and Fuhrman BP: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The Li-quiVent Study Group. N Engl J Med. 1996;335:761-767.
26. Cox CA, Cullen AB, Wolfson MR, and Shaffer TH: In-tratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs. Pediatr Pulmonol. 2001;32: 142-151.
27. Dickson EW, Heard SO, Tarara TE, Weers JG, Bruegge-mann AB, and Doern GV: Liquid ventilation with per-flubron in the treatment of rats with pneumococcal pneumonia. Crit Care Med. 2002;30:393-395.
28. Smith DJ, Gambone LM, Tarara T, Meays DR, Dellamary LA, Woods CM, and Weers J: Liquid dose pulmonary instillation of gentamicin pulmospheres formulations: tissue distribution and pharmacokinetics in rabbits. Pharm Res. 2001;18:1556-1561.
29. Albers GM, Tomkiewicz RP, May MK, Ramirez OE, and Rubin BK: Ring distraction technique for measuring surface tension of sputum: relationship to sputum clearability. J Appl Physiol. 1996;81:2690-2695.
30. Tredici S, Tredici F, Brant DO, Hirschl RB, and Bull JL: Effect of viscosity on instilled perfluorocarbon distribution in rabbit lungs. J Biomech Eng. 2006;128:857-861.
31. Fabiilli ML, Lee JA, Kripfgans OD, Carson PL, and Fowlkes JB: Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions. Pharm Res. 2010;27:2753-2765.
32. Hirayama Y, Hirasawa H, Oda S, Shiga H, Matsuda K, Ueno H, and Nakamura M: Partial liquid ventilation with FC-77 suppresses the release of lipid mediators in rat acute lung injury model. Crit Care Med. 2004;32:2085-2089.
33. Jeng MJ, Kou YR, Sheu CC, and Hwang B: Effects of partial liquid ventilation with FC-77 on acute lung injury in newborn piglets. Pediatr Pulmonol. 2002;33:12-21.
34. Merz U, Klosterhalfen B, Hausler M, Kellinghaus M, Peschgens T, and Hornchen H: Partial liquid ventilation reduces release of leukotriene B4 and interleukin-6 in bronchoalveolar lavage in surfactant-depleted newborn pigs. Pediatr Res. 2002;51:183-189.
35. Kripfgans OD, Fowlkes JB, Miller DL, Eldevik OP, and Carson PL: Acoustic droplet vaporization for therapeutic and diagnostic applications. Ultrasound Med Biol. 2000;26:1177-1189.
36. Moskowitz SM, Foster JM, Emerson J, and Burns JL: Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fi-brosis. J Clin Microbiol. 2004;42:1915-1922.
37. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, and Lagace J: Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aerugi-nosa. Antimicrob Agents Chemother. 1994;38:1090-1095.
38. Hino T, Kawashima Y, and Shimabayashi S: Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy. Adv Drug Deliv Rev. 2000;45:27-45.
39. Moriarty JA, and Grotberg JB: Flow-induced instabilities of a mucus-serous bilayer. J Fluid Mech. 1999;397:1-22.
40. Rubin BK: Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007;52:859-865.
41. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, and Ramsey BW: Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials. 2009;30:256-268.
42. Clausell-Tormos J, Lieber D, Baret JC, El-Harrak A, Miller OJ, Frenz L, Blouwolff J, Humphry KJ, Koster S, Duan H, Holtze C, Weitz DA, Griffiths AD, and Merten CA: Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms. Chem Biol. 2008;15:427-437.
43. Holtze C, Rowat AC, Agresti JJ, Hutchison JB, Angile FE, Schmitz CH, Koster S, Duan H, Humphry KJ, Scanga RA, Johnson JS, Pisignano D, and Weitz DA: Biocompatible surfactants for water-in-fluorocarbon emulsions. Lab Chip. 2008;8:1632-1639.
44. Koster S, Angile FE, Duan H, Agresti JJ, Wintner A, Schmitz C, Rowat AC, Merten CA, Pisignano D, Griffiths AD, and Weitz DA: Drop-based microfluidic devices for encapsulation of single cells. Lab Chip. 2008;8:1110-1115.